검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fruquintinib (Fruquintinib) Institut für Klinische Krebsforsch…·Metastatic Colorectal Adenocarcino… ORR 1.5% |
|---|---|
Overview Program | Fruquintinib |
Overview Company | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Colorectal Adenocarcinoma |
Overview Indication | Metastatic Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive, MSI-H/dMMR, and rare fusion-positive |
PK/PD Species | Mouse, Rat, Human |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Rat, Human |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | Treatment Selection Beyond Second Line in Metastatic Colorectal Cancer: Practical Sequencing of Cytotoxic Salvage Therapy, Anti-angiogenic Agents, Rechallenge Strategies, and Biomarker-Guided Treatments.. Treatment selection beyond second line in metastatic colorectal cancer (mCRC) has evolved from empirical salvage therapy to individualized sequencing. Regorafenib, trifluridine/tipiracil (FTD/TPI… |
Clinical Primary efficacy | ORR 1.5% |
Clinical ORR | 1.5% |
Clinical PFS | 3.7 |
Clinical OS | 7.4 |
Clinical Result source | ClinicalTrials.gov NCT04322539 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fruquintinib (Fruquintinib) Institut für Klinische Krebsforsch…·Metastatic Colorectal Adenocarcino… ORR 1.5% |
|---|---|
Overview Program | Fruquintinib |
Overview Company | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Overview Modality | ANTIBODY |
Overview Target | Metastatic Colorectal Adenocarcinoma |
Overview Indication | Metastatic Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | HER2-positive, MSI-H/dMMR, and rare fusion-positive |
PK/PD Species | Mouse, Rat, Human |
PK/PD Animal (cat.) | Human, Mouse, Rat, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Rat, Human |
Toxicology Animal (cat.) | Human, Mouse, Rat, In vitro |
Toxicology Major finding | Treatment Selection Beyond Second Line in Metastatic Colorectal Cancer: Practical Sequencing of Cytotoxic Salvage Therapy, Anti-angiogenic Agents, Rechallenge Strategies, and Biomarker-Guided Treatments.. Treatment selection beyond second line in metastatic colorectal cancer (mCRC) has evolved from empirical salvage therapy to individualized sequencing. Regorafenib, trifluridine/tipiracil (FTD/TPI… |
Clinical Primary efficacy | ORR 1.5% |
Clinical ORR | 1.5% |
Clinical PFS | 3.7 |
Clinical OS | 7.4 |
Clinical Result source | ClinicalTrials.gov NCT04322539 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교